Home
Resources
Publications
Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis

Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis

Taylor Evart Woo, Paul Kuzel

Skin Therapy Lett. 2019 Mar;24(2):4-6.

PMID: 30970204

Abstract:

Atopic dermatitis is a common cutaneous disease with significant morbidity affecting children and adults. The mainstay of atopic dermatitis therapy has typically included emollients, topical corticosteroids, and topical calcineurin inhibitors. Among the newer advances recently introduced is crisaborole (Eucrisa™), a phosphodiesterase type-4 inhibitor (PDE-4) for the treatment of mild moderate atopic dermatitis. Evidence from phase 3 trials demonstrates crisaborole as an efficacious topical agent with a favorable safety profile and limited systemic exposure. While the efficacy of crisaborole compared to existing therapies remains unknown, crisaborole is a promising candidate in the treatment of atopic dermatitis.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP906673243	Crisaborole		906673-24-3	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: